{"Clinical Trial ID": "NCT02322814", "Intervention": ["INTERVENTION 1:", "Cohort I: Cobimetinib, Paclitaxel", "Participants received a combination of cobimetinib and paclitaxel for 28 days until disease progression, unacceptable toxicity, investigator's decision, death, withdrawal of consent or completion of the study.", "INTERVENTION 2:", "Cohort I: Placebo, Paclitaxel", "Participants received a combination of cobimetinib placebo plus paclitaxel for 28 days until disease progression, unacceptable toxicity, investigator's decision, death, withdrawal of consent or end of study."], "Eligibility": ["Incorporation criteria:", "The Eastern Cooperative Oncology Group (ECOG) achieved a yield of 0 or 1", "- Negative adenocarcinoma of the breast with metastatic or locally advanced measurable disease", "A locally advanced disease should not be susceptible to resection with curative intent", "A measurable disease, according to RECIST, v1.1", "A suitable haematological function and final organ", "Agreement on the use of highly effective contraceptive methods, as indicated in the Protocol", "- Exclusion criteria:", "Specific disease-specific exclusion criteria", "HER2-, ER-positive, or PR-positive breast cancer by local laboratory assessment", "Any prior hormone or targeted therapeutic chemotherapy for triple negative, locally advanced or metastatically inoperative breast cancer (MTNCC)", "Any systemic cancer treatment within 3 weeks prior to cycle 1, Day 1", "Any radioactive treatment at the metastatic site within 28 days of cycle 1, Day 1", "\u2022 Major surgery, open biopsy or significant traumatic injury within 30 days prior to Cycle 1, day 1 or anticipation of major surgery during the study", "Prior exposure to experimental treatment targeting fibrosarcoma (Raf), MAP kinase/ERK kinase (MEK) rapidly accelerated or mitogen-activated protein kinase (MAPK) route", "\u2022 Brain metastases (symptomatic or non-symptomatic) that have not previously been treated are progressive or require any type of treatment (e.g., radiotherapy, surgery or steroids) to control the symptoms of brain metastases within 30 days prior to the first treatment dose", "Specific exclusion criteria for cobimetinib", "Background or evidence of a retinal pathology on ophthalmological examination that is considered a risk factor for neurosensorial retinal detachment/central serous chorioretinopathy (CSCR), retinal venous occlusion (RVO) or neovascular macular degeneration", "Cobimetinib is metabolised by the hepatic enzyme of cytochrome P3A4 (CYP3A4). CYP3A4/5 inhibitors and inducers should be avoided.", "Atezolizumab-specific exclusion criteria (cohorts II and III only)", "History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeral or humanized antibodies or fusion proteins", "\u2022 Hypersensitivity or known allergy to biopharmaceuticals produced in Chinese hamster ovarian cells or in any component of the formulation of atezolizumab", "\u2022 History of autoimmune disease", "\u00b7 Pre-transplantation of allogenous stem cells or solid organs", "\u2022 History of idiopathic pulmonary fibrosis (including pneumonopathy), drug-induced pneumonia, pneumonia (i.e. obliterating bronchiolite, organising cryptogenic pneumonia), or signs of active pneumonopathy during chest tomography (CT) screening", "Positive test for human immunodeficiency virus (HIV)", "- Active hepatitis B (defined as having a positive surface antigen of hepatitis B [HBsAg] or a positive deoxyribonucleic acid test of hepatitis B virus [HBV] [DNA] in screening) or hepatitis C", "Active tuberculosis", "The receipt of a live attenuated vaccine within 4 weeks of randomization or anticipation of such a live attenuated vaccine will be required during the study.", "Previous treatment with a differentiation group (CD) 137 (CD137) agonists or immune blocker treatments, including protein associated with T-cells anticytotoxic 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1) or anti-programmed death-1 (anti-PD-L1) therapeutic antibodies", "- Treatment with systemic immunostimulatory agents (including, but not limited to, interferons or Interlukin-2 [IL-2]) within 4 weeks or 5 half-lives of the medicinal product (any shorter) prior to randomisation", "Treatment with systemic corticosteroids or other systemic immunosuppressive medicinal products within 2 weeks prior to randomisation, or anticipated need for systemic immunosuppressive medicinal products during trial", "Criteria for cardiac exclusion", "Clinically significant history of cardiac dysfunction", "The QT interval corrected for screening is greater than (>) 480 milliseconds (ms) (average of tripled screening measures)", "The left ventricular ejection fraction is less than the lower institutional limit of normal or less than 50% (%), whichever is lower.", "General exclusion criteria", "No other cases of malignancy or continuous malignancy that could interfere with the interpretation of the pharmacodynamic test or efficacy", "Pregnancy (positive serum pregnancy test) or lactation", "A serious medical or psychiatric disease that is uncontrolled", "Active infection requiring IV antibiotics on cycle 1, day 1", "Participants with a history of hypersensitivity reactions to paclitaxel or other medicinal products formulated in Cremophor\u00ae EL (polyoxyethyl castor oil) or nab-paclitaxel and any of the excipients"], "Results": ["Performance measures:", "Cohort I: Survival without progression, determined by the researcher using the criteria for assessing responses in solid tumours Version 1.1 (RECIST v1.1)", "The PFS was defined as the period from randomization to the first onset of progression or relapse of the disease, as determined by the investigator, using RECIST v1.1.", "Time frame: randomization until disease progression or relapse, whichever occurs first (up to approximately 3.5 years)", "Results 1:", "Title of arm/group: Cohort I: Cobimetinib, Paclitaxel", "Description of the arm/group: Participants received a combination of cobimetinib and paclitaxel in the 28-day cycles until disease progression, unacceptable toxicity, investigator's decision, death, withdrawal of consent or completion of the study.", "Total number of participants analysed: 43", "Median (95% confidence interval)", "Unit of measure: Weeks 16.43 (8.14-31.14)", "Results 2:", "Title of the arm/group: Cohort I: Placebo, Paclitaxel", "Arm/group description: Participants received a combination of cobimetinib placebo plus paclitaxel for 28 days until disease progression, unacceptable toxicity, investigator's decision, death, withdrawal of consent or end of study.", "Total number of participants analysed: 47", "Median (95% confidence interval)", "Unit of measure: Weeks 23.71 (18.14 to 32.14)"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/16 (37.50 per cent)", "Febrile neutropenia * 0/16 (0.00 %)", "Neutropenia * 0/16 (0.00 %)", "Incompetence of the Mitral valve * 1/16 (6.25 per cent)", "Heart failure * 0/16 (0.00 %)", "Cardiac arrest * 0/16 (0.00 %)", "Papilloedema * 0/16 (0.00 %)", "Diarrhoea * 0/16 (0.00 %)", "Intestinal occlusion * 0/16 (0.00 %)", "Nausea * 0/16 (0.00 %)", "Vomiting * 0/16 (0.00 %)", "Pyrexia * 2/16 (12.50%)", "Adverse Events 2:", "Total: 9/43 (20.93 per cent)", "Febrile neutropenia * 1/43 (2.33%)", "Neutropenia * 0/43 (0.00 %)", "Incompetence of the mitral valve * 0/43 (0.00 %)", "* 1/43 (2.33%)", "Cardiac arrest * 0/43 (0.00 %)", "Papilloedema * 0/43 (0.00 %)", "Diarrhoea * 0/43 (0.00 %)", "Intestinal occlusion * 0/43 (0.00 %)", "Nausea * 0/43 (0.00 %)", "Vomiting * 0/43 (0.00 %)", "Pyrexia * 0/43 (0.00 %)"]}